To accelerate innovation and upgrading, pharmaceutical companies are constantly introducing new drugs

In recent years, driven by multiple forces such as policies and capital, China's biomedical industry has entered a stage of rapid development.
Many places have regarded this industry as a new economic growth point and have continued to increase their layout
.
It is worth noting that, in the context of increasing policy support for pharmaceutical innovation, the capital market for innovative drugs is still rising, and a large number of listed pharmaceutical companies are also racing to introduce new drugs in the near future to enhance their innovation capabilities
.
According to incomplete statistics, in October this year, at least eight Chinese biopharmaceutical companies have reached new drug introduction cooperation, including Shanghai Pharmaceuticals, Luoxin Pharmaceutical, Huadong Pharmaceutical, Yehui Pharmaceutical, China Resources Double Crane, and Hansen Pharmaceuticals
.
Among them, Shanghai Pharmaceuticals and Hansen Pharmaceuticals reached two cooperations within one month
.
For example, on October 8, Shanghai Pharmaceuticals announced that it would acquire Guizhou Shengnuo Biotechnology Co.
, Ltd.
(hereinafter referred to as "Shenuo Pharmaceutical") new acid inhibitor X842 raw materials and materials for an amount of no more than RMB 690 million (excluding sales commissions).
Exclusive commissioned production of preparations in China (including Hong Kong, Macau and Taiwan) and industrial sales rights for all indications
.
Later, on October 28, Shanghai Pharmaceuticals announced that it would obtain a new probiotic drug KBL697 and KBL693 project from KoBioLabs for a transaction amount of no more than US$107.
25 million (excluding sales commissions) to develop, produce, register, distribute, and sell in China.
, Marketing, promotion and sublicensing rights, including all indications of KBL697 and KBL693 as medicines
.
On the whole, the introduction of products from outside has become one of the important ways for biomedical companies to expand their product pipelines and explore more innovative therapies
.
The analysis believes that in the process of continuous deepening of the medical reform, the policy level to encourage pharmaceutical innovation is becoming more and more clear, and many places have successively released the development goals of the biomedical industry in the next few years
.
These documents and plans are releasing stronger signals of support for innovation, further promoting the upgrade of the industry pattern from follow-up innovation to hard-core innovation
.
In this context, the industry believes that in the future, more and more pharmaceutical companies will frequently introduce new drugs, enrich their product pipelines through the license in (authorized introduction) model, and enhance their innovation capabilities..
However, the industry has also pointed out that although the introduction of new drug models can quickly expand the product pipeline, the lcense in model is only a convenient way to expand the product pipeline.
It cannot be relied on for a long time.
Only companies with continuous R&D capabilities and true innovation capabilities can gain access to the capital market.
More recognition
.
It is understood that, in fact, the state has already begun to crack down on "pseudo-innovation" of pharmaceutical companies through regulation
.
In the past two years, dozens of local innovative new drug research and development companies have won capital favors and landed in the capital market with the License in business model, such as Genting Xinyao, Zai Lab, and Tianjing Bio
.
However, in July this year, the Shanghai Stock Exchange released an announcement on the results of the 48th review meeting of the 2021 Sci-tech Innovation Board Listing Committee, showing that Shanghai Haihe Pharmaceutical Research and Development Co.
, Ltd.
(referred to as "Haihe Pharmaceutical") has suspended the review and requested Haihe Pharmaceutical to explain Whether it has made improvements to the imported products, whether it has independent research and development capabilities, etc.
, indicate that the supervision and anti-counterfeiting innovation of pharmaceutical companies has begun to be gradually strengthened
.
The industry believes that with the advancement of "Healthy China 2030", the difficulty of reviewing and approving low-value drugs will gradually increase, and the China Securities Regulatory Commission will also step up its efforts to veto the capital-assisted "License in" model, and the country will strictly control counterfeit innovation from the regulatory level.
Will continue to increase
.
In this context, pharmaceutical companies need to further enhance their true innovation capabilities
.
In general, "License in" is not a simple purchase.
Companies must also improve their level of innovation and focus on the clinical value of drugs in order to move toward a broader future
.
The industry predicts that under the general trend of innovation in the future, independent research and development and license in must complement each other, and will accompany them for a long time.
In the future, this will also become a basic model for Chinese new drug research and development companies
.